PHARMEA
The PharMEA Platform: Multi-Electrode Array technology based platform for industrial pharmacology and toxicology drug screening
| Coordinatore | AYANDA BIOSYSTEMS SA
Organization address
address: "Parc Scientific EPFL, PSE" contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 1˙885˙200 € |
| EC contributo | 1˙452˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2008-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-09-01 - 2011-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AYANDA BIOSYSTEMS SA
Organization address
address: "Parc Scientific EPFL, PSE" contact info |
CH (LAUSANNE) | coordinator | 517˙500.00 |
| 2 |
BIO-LOGIC
Organization address
address: RUE DE L'EUROPE 1 contact info |
FR (CLAIX) | participant | 656˙400.00 |
| 3 |
CAPSANT NEUROTECHNOLOGIES LIMITED
Organization address
address: VENTURE ROAD 2 contact info |
UK (SOUTHAMPTON) | participant | 244˙500.00 |
| 4 |
HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALE
Organization address
address: RUE DE LA JEUNESSE 1 contact info |
CH (DELEMONT) | participant | 16˙800.00 |
| 5 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 8˙400.00 |
| 6 |
Synome Ltd
Organization address
address: MONETA BUILDING BABRAHAM RESEARCH CAMPUS contact info |
UK (Cambridge) | participant | 8˙400.00 |
| 7 |
HAUTE ECOLE D'INGENIERIE ET DE GESTION DU CANTON DE VAUD
Organization address
address: ROUTE DE CHESEAUX 1 contact info |
CH (YVERDON-LES-BAINS) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The project PharMEA is based on the technology platform of multi-electrode arrays, which have been widely used for electrophysiological experiments on neuronal and cardiac tissues. Some of the key advantages of MEA technology include ease of use, non-invasive measurements and simultaneous multi-site recording & stimulation capability. Despite these key advantages, MEA technology utilization has remained largely confined in academic research institutions, primarily due to the low throughput of currently available MEA-based tools. The PharMEA project addresses these shortcomings by developing novel MEA tools and applications that will significantly increase throughput of MEA experiments, facilitate MEA experiments on various culture models, as well as associated applications tailored for the drug discovery industry. Specifically, the new MEA tools will increase the number of channels or measurement sites for simultaneous recording and stimulation from about 120 channels today to 1024 channels, along with the corresponding intelligent data handling and processing strategies. Furthermore, the PharMEA project will develop and automate biological assay protocols that are common in ion-channel based drug discovery activities, as we this will add significant value to and bring out the benefit of the proposed tools. Altogether, the results of this project will accelerate the uptake of MEA tools in the drug discovery industry, thereby significantly increasing the market opportunity and competitive edge of the various sponsoring SMEs in the lucrative drug discovery industry.'